2019–2020 Drug Updates in Hematologic Malignancies

During JADPRO Live Virtual 2020, Heidi D. Finnes, PharmD, BCOP, FHOPA, discussed the pharmacology and indications of medications approved from late 2019 to late 2020 for the management of patients with hematologic malignancies, reviewed pivotal clinical trial data, and covered the adverse events of...

Descripción completa

Detalles Bibliográficos
Autor principal: Finnes, Heidi D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2021
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087224/
https://www.ncbi.nlm.nih.gov/pubmed/34084575
http://dx.doi.org/10.6004/jadpro.2021.12.3.12
Descripción
Sumario:During JADPRO Live Virtual 2020, Heidi D. Finnes, PharmD, BCOP, FHOPA, discussed the pharmacology and indications of medications approved from late 2019 to late 2020 for the management of patients with hematologic malignancies, reviewed pivotal clinical trial data, and covered the adverse events of these hematologic medications.

Ejemplares similares